Open AccessEmphasizing on heat shock protein 90′s utility in head and neck squamous cell carcinoma treatment
Author(s) -
Samapika Routray,
Aparajita Sunkavalli,
Niharika Swain,
Akhil A. Shankar
Publication year - 2013
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.126451
Subject(s) - heat shock protein , cancer research , geldanamycin , medicine , head and neck squamous cell carcinoma , hsp90 , head and neck cancer , myeloid leukemia , hsp90 inhibitor , cancer , oncology , pathology , biology , biochemistry , gene
Heat shock protein 90 (Hsp90) a member of the heat shock proteins (HSPs) family, is an adenosine triphosphate dependent molecular chaperone protein, which integrates multiple oncogenic pathways. Clinically, encouraging results have been demonstrated in melanoma, acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple myeloma using the first generation Hsp90 inhibitors. Hsp90 as the target of anticancer activity of geldanamycin sparked much interest in the inhibition of Hsp90 as a strategy for the treatment of cancer. Hsp90 inhibitors demonstrate rapid clearance from normal tissues and the blood compartment with prolonged retention in tumors making it a sought after modality for treating cancer. Our review emphasizes its role as anti-cancer therapy for head and neck squamous cell carcinoma.